Levels of S100B are raised in female patients with schizophrenia

Hdl Handle:
http://hdl.handle.net/10147/292885
Title:
Levels of S100B are raised in female patients with schizophrenia
Authors:
O’Connell, Kara; Thakore, Jogin; Dev, Kumlesh K
Citation:
BMC Psychiatry. 2013 May 24;13(1):146
Issue Date:
24-May-2013
URI:
http://dx.doi.org/10.1186/1471-244X-13-146; http://hdl.handle.net/10147/292885
Abstract:
Abstract Background The neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of S100B in schizophrenia and influence of age, gender, medication and illness severity were examined. Methods Serum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle, metabolic and illness severity parameters were correlated with S100B concentrations. Results Data showed raised serum levels of S100B in schizophrenia female patients, but not male patients, compared to controls. Correlation analysis demonstrated a positive association between S100B serum concentrations and BMI. Conclusions This study supports previous findings that adipocytes may contribute to S100B serum concentrations in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication, lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorO’Connell, Kara-
dc.contributor.authorThakore, Jogin-
dc.contributor.authorDev, Kumlesh K-
dc.date.accessioned2013-05-28T10:30:28Z-
dc.date.available2013-05-28T10:30:28Z-
dc.date.issued2013-05-24-
dc.identifier.citationBMC Psychiatry. 2013 May 24;13(1):146-
dc.identifier.urihttp://dx.doi.org/10.1186/1471-244X-13-146-
dc.identifier.urihttp://hdl.handle.net/10147/292885-
dc.description.abstractAbstract Background The neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of S100B in schizophrenia and influence of age, gender, medication and illness severity were examined. Methods Serum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle, metabolic and illness severity parameters were correlated with S100B concentrations. Results Data showed raised serum levels of S100B in schizophrenia female patients, but not male patients, compared to controls. Correlation analysis demonstrated a positive association between S100B serum concentrations and BMI. Conclusions This study supports previous findings that adipocytes may contribute to S100B serum concentrations in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication, lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.-
dc.titleLevels of S100B are raised in female patients with schizophrenia-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderKara O’Connell et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2013-05-27T23:06:08Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.